Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial.

Wei, Chenchen; Wang, Jeffrey; Foster, Lydia D; Yeatts, Sharon D; Moy, Claudia; Mocco, J; Selim, Magdy

Wei, Chenchen; Wang, Jeffrey; Foster, Lydia D; Yeatts, Sharon D; Moy, Claudia; Mocco, J; Selim, Magdy.

Afiliação

Wei C; Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.W., J.W., M.S.).
Wang J; Department of Neurology, The Affiliated Hospital of Qingdao University, China (C.W.).
Foster LD; Department of Neurology, West China Hospital, Sichuan University, Chengdu, China (C.W.).
Yeatts SD; Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.W., J.W., M.S.).
Moy C; Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.D.F., S.D.Y.).
Mocco J; Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.D.F., S.D.Y.).
Selim M; National Institute of Neurological Disorders and Stroke, Bethesda, MD (C.M.).

Stroke ; 53(4): 1149-1156, 2022 04.

Article em En | MEDLINE | ID: mdl-34789008

Assuntos

Desferroxamina; Hematoma; Humanos; Hemorragia Cerebral; Desferroxamina/uso terapêutico; Hematoma/tratamento farmacológico; Razão de Chances; Resultado do Tratamento

Palavras-chave

deferoxamine; hematoma; hemorrhage; iron; odds ratio

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desferroxamina / Hematoma Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Stroke Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google